Non-Executive Chair
Advisory Board Member
A spin-out of Cambridge Cognition in 2021, Monument Therapeutics (Monument Tx) is an independent UK based biotech, developing products to treat serious diseases of the central nervous system. Specialists in the use of validated digital biomarkers to enable better neuroscience drug development, Monument Tx’s proprietary digital biomarkers, and novel formulations of well-characterised CNS-active small molecules, together permit rapid progress in clinical development.
With fresh investment secured from a new investor and the current Chair transitioning to an Advisory role, Monument Tx’s Senior Leadership Team and Board sought to appoint a new Non-Executive Chair with international experience and networks.
Monument Tx CEO, Jenny Barnett, partnered with leading life sciences executive search firm PIR International to lead this critical appointment. Leveraging its rigorous research methodology and extensive industry network, PIR International conducted a thorough global search, led by Sally Hope, Tom Bradley, and Paul Hoey, resulting in a strong shortlist of highly qualified, industry leading candidates.
Following a structured selection process, Monument Tx appointed Robert S. Radie (Bob), former President, CEO, and Director of Topaz Pharmaceuticals, as Non-Executive Chair of the Board in April 2025. The strength of the shortlist also enabled Monument Tx to bolster its Advisory Board with the appointment of Dr. Heather Preston, a seasoned healthcare venture capitalist with over two decades of experience. Dr. Preston brings deep expertise and a long-standing commitment to advancing treatments for schizophrenia, having previously served on the Board of Karuna Therapeutics ahead of its $14 billion acquisition by Bristol Myers Squibb in 2024.
Comment from Jenny Barnett, Chief Executive Officer, Monument Therapeutics: “Going into this search we already had a strong network of advisors from the UK biotech industry, so we tasked PIR International specifically with finding us candidates from outside our existing network. We’re a small and tightknit company so it was important to us that the new non-exec Chair would fit the culture, as well as bring new ideas and experience to the team. We were delighted with the strong shortlist PIR International produced, and with their assistance we are convinced we appointed absolutely the right candidate.”
Comment from Bob Radie: “It has been a pleasure working with Paul, Tom, and Sally from the moment they introduced me to this exciting opportunity with Monument Therapeutics. They helped me to gain some initial information on the company and then facilitated a very comfortable and timely introduction to Jenny and her team as well as other members of the board of directors. I have been impressed with PIR’s approach and am very excited to be part of next phase of growth at Monument.”
Jenny Barnett, Chief Executive Officer, Monument Therapeutics
